Amgen Inc. (NASDAQ:AMGN) Receives $380.43 Average Target Price from Brokerages

Shares of Amgen Inc. (NASDAQ:AMGN) have been assigned an average recommendation of “Hold” from the thirty-one research firms that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, thirteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $380.4286.

A number of research analysts recently weighed in on the stock. Piper Sandler lifted their price objective on shares of Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Bank of America raised their price target on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Scotiabank lifted their price target on Amgen from $385.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Guggenheim increased their price objective on Amgen from $343.00 to $388.00 and gave the stock a “neutral” rating in a report on Monday, August 10th. Finally, Daiwa Securities Group reduced their target price on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a report on Wednesday, May 13th.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha demonstrated a meaningful mortality benefit. Amgen reported that Repatha reduced the risk of death by 20% in more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. The findings came from a prespecified analysis of the Phase 3 VESALIUS-CV trial presented at the 2026 European Society of Cardiology Congress. The result could support broader use of Repatha beyond cholesterol reduction and strengthen one of Amgen’s key revenue drivers. Amgen Repatha clinical results
• Positive Sentiment: Analyst sentiment and performance comparisons remain supportive. Commentary says AMGN has outperformed the broader market over the past year, with analysts moderately bullish on its future prospects. Erste Group Bank also issued a positive forecast for Amgen’s earnings, adding to the favorable outlook. Amgen stock performance comparison
• Neutral Sentiment: Industry growth could provide a secondary opportunity. A new report identifies Amgen among companies participating in the expanding palmoplantar pustulosis market, driven by increased diagnosis and demand for biologic treatments. However, the report does not identify a specific Amgen product or provide a material revenue forecast, so the immediate stock impact is likely limited. Palmoplantar pustulosis market report

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Anfield Capital Management LLC raised its position in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the period. Dogwood Wealth Management LLC increased its holdings in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares during the period. Tower View Wealth Management LLC increased its holdings in shares of Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares during the period. Manning & Napier Advisors LLC boosted its holdings in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the period. Finally, Evergreen Advisors LLC purchased a new stake in Amgen during the 1st quarter valued at about $37,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 0.6%

Shares of AMGN opened at $429.88 on Friday. Amgen has a fifty-two week low of $269.77 and a fifty-two week high of $447.03. The business has a 50-day moving average of $390.35 and a 200 day moving average of $365.09. The firm has a market cap of $232.41 billion, a P/E ratio of 26.72, a price-to-earnings-growth ratio of 3.12 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts forecast that Amgen will post 22.97 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio is currently 62.65%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.